Form 4: Bio-Rad Laboratories: CEO Norman Schwartz Reports Changes in Beneficial Ownership

Norman Schwartz, Chairman and CEO of Bio-Rad Laboratories, reports changes in his beneficial ownership of company stock, including the disposal of Bio-Rad B Common Stock and acquisition of Restricted Stock Units.

Summary

• Norman Schwartz, Chairman and CEO of Bio-Rad Laboratories, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The report indicates the disposal of 438,238 Bio-Rad A Common Stock and 361,466 Bio-Rad B Common Stock.
• He also indirectly owns 13,006 Bio-Rad B Common Stock through his spouse and 4,060,054 Bio-Rad B Common Stock through Blue Raven Partners, L.P.
• Schwartz acquired 13,822 Restricted Stock Units (RSUs) on September 6, 2024, which vest over four years.
• Each RSU represents a contingent right to receive one share of Bio-Rad Class A common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports changes in stock ownership, which doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of 13,822 Restricted Stock Units indicates continued alignment of the CEO's interests with the company's long-term performance.

Future Outlook

The vesting schedule of the Restricted Stock Units is over four years, at 25% per year on the yearly anniversary date of the grant.

Industry Context

Changes in beneficial ownership are routinely monitored by investors as they can provide insights into management's confidence in the company's prospects. This filing is a standard regulatory requirement for corporate insiders.

Stakeholder Impact

• The changes in beneficial ownership may be of interest to shareholders as it reflects the CEO's stake in the company.

Key Dates